DLL3 targeting chimeric antigen receptors and binding agents
AssigneesAllogene Therapeutics, Inc., Pfizer Inc.
InventorsYi Zhang, Thomas John Van Blarcom, Siler Panowski, Silvia K. Tacheva-Grigorova, Barbra Johnson Sasu
Life of this patent
Estimating the term…
Abstract
Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
Claims26
An isolated polynucleotide encoding a chimeric antigen receptor comprising an extracellular domain, a hinge domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain comprises a DLL3 antigen binding domain that specifically binds to DLL3, and wherein the antigen binding domain comprises:
- (a) a variable heavy chain CDR1 comprising the amino acid sequence shown as SEQ ID NO:
- 109;
- (b) a variable heavy chain CDR2 comprising the amino acid sequence shown as SEQ ID NO:
- 110;
- (c) a variable heavy chain CDR3 comprising the amino acid sequence shown as SEQ ID NO:
- 111;
- (d) a variable light chain CDR1 comprising the amino acid sequence shown as SEQ ID NO:
- 112;
- (e) a variable light chain CDR2 comprising the amino acid sequence shown as SEQ ID NO:
- 113;
- and
- (f) a variable light chain CDR3 comprising the amino acid sequence shown as SEQ ID NO:
- 114.
An isolated polynucleotide encoding an anti-DLL3 binding agent comprising an antigen binding domain of an antibody that specifically binds to DLL3, wherein the antigen binding domain comprises:
- (a) a variable heavy chain CDR1 comprising the amino acid sequence shown as SEQ ID NO:
- 109;
- (b) a variable heavy chain CDR2 comprising the amino acid sequence shown as SEQ ID NO:
- 110;
- (c) a variable heavy chain CDR3 comprising the amino acid sequence shown as SEQ ID NO:
- 111;
- (d) a variable light chain CDR1 comprising the amino acid sequence shown as SEQ ID NO:
- 112;
- (e) a variable light chain CDR2 comprising the amino acid sequence shown as SEQ ID NO:
- 113;
- and
- (f) a variable light chain CDR3 comprising the amino acid sequence shown as SEQ ID NO:
- 114.
Dependencies are inferred from the claim text.